Transverse Myelitis Occurring After mRNA Vaccination... Causality Recognized

Vaccine [Image source=Yonhap News]

[Asia Economy Reporter Byeon Seon-jin] Causality has been recognized for transverse myelitis occurring after messenger ribonucleic acid (mRNA) vaccine administration, and it will be included in the compensation support targets.

According to the quarantine authorities, the COVID-19 vaccination damage compensation expert committee recently held its 3rd meeting to discuss changes in the review criteria for transverse myelitis occurring after vaccination and resolved to add it as a support target under "suspected related diseases."

This is a follow-up measure after the "COVID-19 Vaccine Safety Research Center" announced on the 31st of last month that the risk of acute transverse myelitis significantly increased with mRNA vaccines (Pfizer, Moderna). Until now, only transverse myelitis occurring after viral vector vaccines (AstraZeneca, Janssen) was supported as a "suspected related disease." The compensation committee explained that the decision was made after comprehensively considering not only the research center's analysis results but also prior overseas studies.

Additionally, the compensation committee reviewed a total of 1,067 new cases of adverse reactions reported after COVID-19 vaccination and recognized causality in 166 cases (15.6%), deciding to provide compensation. They stated that this judgment was made based on a comprehensive assessment of medical records, epidemiological investigations, underlying diseases, medical history, and clinical progress of adverse reactions after vaccination.

The cumulative number of COVID-19 vaccination damage compensation applications is 93,464, with 82,448 cases (88.2%) reviewed. Among these, a total of 23,001 cases (27.9%), including 17 deaths, have been decided for compensation.

This content was produced with the assistance of AI translation services.